| Project/Area Number |
24390222
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
sasaki tsutomu 大阪大学, 医学部附属病院, 助教 (20534879)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
kitagawa kazuo 東京女子医科大学, 医学部, 教授 (70301257)
nagaoka yasuo 関西大学, 工学部, 教授 (90243039)
takemori hiroshi 国立研究開発法人医薬基盤, 健康・栄養研究所, プロジェクトリーダー (90273672)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
mochiduki hideki 大阪大学, 医学系研究科, 教授 (90230044)
uesato shinnichi 関西大学, 工学部, 教授 (50111969)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2014: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2012: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Keywords | 脳虚血 / シグナルトランスダクション / ＣＲＥＢ / ＳＩＫ（塩誘導性キナーゼ） / ＨＤＡＣ（ヒストン脱アセチル化酵素） / パーキンソン病 / ＨＤＡＣ阻害剤 / 創薬 / CRTC / SIK（塩誘導性キナーゼ） / HDAC / アポトーシス / CREB / エピゲノム / TORC / 低分子化合物 / 神経疾患 / 脳卒中 |
|---|
| Outline of Final Research Achievements |
Although patients suffering from neurological disease including both neurodegenerative disease and stroke will increase dramatically in the coming years, there are currently a few effective drugs for neuronal protection and disease-modifying therapy. To provide new therapies to overcome these disease, we have examined both roles and mechanisms of salt-inducible kinase (SIK)-CREB-CRTC signaling and both histone deacetylases (HDACs) - histone acetylation. These cascade has been attributed to both not only neuronal injury but also inflammation in many neurological diseases. Among the original HDAC inhibitor library, we identified a novel HDAC1/2 isoform-specific inhibitor for Parkinson's disease and stroke. The isoform selective inhibition of HDAC may pave the way to new strategies for neurological disease.
|
